Inequalities in health: Access to treatment for HIV/AIDS

Annali dell'Istituto Superiore di Sanita

Volumn 43, Issue 4, 2007, Pages 313-316

  Giuliano, Marina ^a   Vella, Stefano ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Access to health care; Developing countries; Highly active antiretroviral therapy; HIV

Indexed keywords

AFRICA SOUTH OF THE SAHARA; ARTICLE; ASIA; DEVELOPED COUNTRY; DEVELOPING COUNTRY; EASTERN EUROPE; ECONOMICS; HEALTH; HEALTH CARE DELIVERY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL COOPERATION; METHODOLOGY; STATISTICS;

AFRICA SOUTH OF THE SAHARA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASIA, CENTRAL; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; EUROPE, EASTERN; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HIV INFECTIONS; HUMANS; INTERNATIONAL COOPERATION; WORLD HEALTH;

EID: 38949207493     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Joint United Nations Program on HIV/AIDS and World Health Organization. AIDS epidemic update. Geneva, Switzerland: UNAIDS/WHO; 2006. Available from: http://www.unaids.org; last visited: 27/06/2007.
2. Delta Coordinating Committee. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-91.
3. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
4. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
5. th session (2000): United Nations Millennium Declaration (A/RES/55/2). Available from: http://www.un.org/millennium/declaration/ ares552e.htm; last visited: 26/06/2007.
6. Greener R. The impact of HIV/AIDS on poverty and inequality. In: Haacker M (Ed.). The macroeconomics of HIV/AIDS. Washington, DC: International Monetary Fund; 2004. p 167-81.
7. WHO/UNAIDS/UNICEF. Towards universal access. Scaling-up priorities HIV/AIDS interventions in the health sector. (Progress report, April 2007), Available from: http://www.un-aids.org; last visited: 26/06/2007.
8. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, Sutherland D, Vitoria M, Guerna T, De Cock K. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006;368:505-10.
9. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, Rachlis B, Wu P, Cooper C, Thabane L, Wilson K, Guyatt GH, Bangsberg DR. Adherence to antiretroviral therapy in Sub-Saharan Africa and North America: A meta-analysis. JAMA 2006;296:679-90.
10. Abadia-Barrero CE, Castro A. Experiences of stigma and access to HAART in children and adolescents living with HIV/AIDS in Brazil. Soc Sci & Med 2006;62:1219-28.
11. Cunningham WE, Sohler NL, Tobias C, Drainoni ML, Bradford J, Davis C, Cabral HJ, Cunningham CO, Eldred L, Wong MD. Health services utilization for people with HIV infection: comparison of a population targeted for outreach with the US population in care. Med Care 2006;44:1038-47.
12. Borrell C, Rodriguez-Sanz M, Pasarin I, Brugal MT, Garcia-de-Olalla P, Dell'Olmo MM, Caylà J. AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a National Health System? Eur J Public Health 2006;16:601-8.
13. Wallace RG. AIDS in the HAART era: New York's heterogeneous geography. Soc Sci Med 2003;1155-71.
14. th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA: Feb. 25-28, 2007.
15. Dray-Spira R, Spire B, Heard I, Lert F, the VESPA Study group. Heterogeneous response to HAART across a diverse population of people living with HIV: Results from the ANRS-EN12-VESPA study. AIDS 2007;21(Suppl 1):S5-S12.